



Ambu acquires patents that support approx. 300m DKK of Ambu's existing revenue

Investment is in line with the current strategy plan, and the financial outlook for 2015/16 is not impacted.

Today, 7 April, 2016, Ambu has concluded an agreement on the acquisition of intellectual property rights related to one of Ambu's most important product lines: Breathing circuits. The agreement gives Ambu ownership of important patents within the circuit product portfolio which in total generates an annual revenue of more than USD 45m, mainly in USA.

"We have used this intellectual property for years and paid a royalty on our sales. The acquisition supports a major part of Ambu's business. With this acquisition Ambu gains full control of this important IP and thereby better ability to develop new products within this important area. This investment supports our long-term strategy and strengthens the circuit product group in which Ambu is already the leading player on the North American market," says Lars Marcher, President and CEO.

The purchase price of USD 9m will be reported in the cash flow statement as "Acquisitions of companies and technology etc." in the interim report for Q2 2015/16 to be announced on May 3, 2016. The purchase price will be amortized over the remaining life-time of the patents and the yearly amortization going forward will not differ significantly from the royalties paid historically. The acquisition of the patents does not affect the previously announced outlook for EBIT margin, free cash flows or gearing.

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: Im@ambu.com

Ambu A/S Baltorpbakken 13 DK-2750 Ballerup Tel.: +45 7225 2000 CVR no.: 63 64 49 19 www.ambu.com

About Ambu

Since 1937, breakthrough ideas have driven Ambu's work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu bag and the legendary BlueSensor[™] electrodes to our latest landmark solutions such as the aScope[™] – the world's first single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medtech companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu has more than 2,300 employees in Europe, North America and the Asia Pacific region. You can find more information about Ambu on our website: www.ambu.com.

Ambu

Company announcement no. 28 2015/16